Valeant Pharma (VRX) Talks to Sell Salix to Takeda for $10B Have Broken Down - DJ
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 30, 2016 10:05 AM EST)
Talks between Valeant Pharma (NYSE: VRX) and Takeda regarding a $10 billion deal for Salix have broken down, according to Dow Jones. The report said talks failed due to disagreements over price. Valeant now plans to focus on building the stomach-drug business.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- DuPont (DD), Dow Chemical (DOW) Said to Face EU Concerns Over Research Spending - Bloomberg
- MSC Software draws takeover interest from Apax, Advent - Bloomberg
Create E-mail Alert Related CategoriesHot M&A, Mergers and Acquisitions, Rumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!